96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-003141-10-BE (EUCTR) | 29/09/2014 | 26/09/2014 | Invloed van UDCA op fecale galzoutensamenstelling van IBD patiënten: piloot studie. | Invloed van UDCA op fecale galzoutensamenstelling van IBD patiënten: piloot studie. | Crohn's disease or colitis ulcerosa MedDRA version: 17.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 17.1;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: UrsoFalk® 250 mg tabletten. Product Name: UrsoFalk INN or Proposed INN: ursodeoxycholic acid Other descriptive name: URSODEOXYCHOLIC ACID | Ghent University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 4 | Belgium |